• Citer

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

par Colleoni, Marco Angelo;Luo, Weixiu;Karlsson, Per;Chirgwin, Jacquie;Aebi, Stefan;Jerusalem, Guy;Neven, Patrick ;Hitre, Erika;Graas, Marie-Pascale;Simoncini, Edda;Kamby, Claus;Thompson, Alastair M;Loibl, Sibylle;Gavilá, Joaquín;Kuroi, Katsumasa;Marth, Christian;Müller, Bettina;O'Reilly, Seamus;Di Lauro, Vincenzo;Gombos, Andrea ;Ruhstaller, Thomas;Burstein, Harold;Ribi, Karin;Bernhard, Jürg;Viale, Giuseppe;Maibach, Rudolf;Rabaglio-Poretti, Manuela;Gelber, Richard D;Coates, Alan A.S.;Di Leo, Angelo ;Regan, Meredith;Goldhirsch, Aron;SOLE Investigators,
Référence Lancet oncology, 19, 1, page (127-138)
Publication Publié, 2018

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Auteur:	Colleoni, Marco Angelo; Luo, Weixiu; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Hitre, Erika; Graas, Marie-Pascale; Simoncini, Edda; Kamby, Claus; Thompson, Alastair M; Loibl, Sibylle; Gavilá, Joaquín; Kuroi, Katsumasa; Marth, Christian; Müller, Bettina; O'Reilly, Seamus; Di Lauro, Vincenzo; Gombos, Andrea; Ruhstaller, Thomas; Burstein, Harold; Ribi, Karin; Bernhard, Jürg; Viale, Giuseppe; Maibach, Rudolf; Rabaglio-Poretti, Manuela; Gelber, Richard D; Coates, Alan A.S.; Di Leo, Angelo; Regan, Meredith; Goldhirsch, Aron; SOLE Investigators,
Informations sur la publication:	Lancet oncology, 19, 1, page (127-138)
Statut de publication:	Publié, 2018
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Aged
	Antineoplastic Agents -- administration & dosage -- adverse effects
	Aromatase Inhibitors -- administration & dosage -- adverse effects
	Biomarkers, Tumor -- analysis
	Breast Neoplasms -- chemistry -- drug therapy -- mortality -- pathology
	Chemotherapy, Adjuvant
	Disease-Free Survival
	Drug Administration Schedule
	Female
	Humans
	Letrozole
	Middle Aged
	Nitriles -- administration & dosage -- adverse effects
	Postmenopause
	Receptor, ErbB-2 -- analysis
	Receptors, Estrogen -- analysis
	Receptors, Progesterone -- analysis
	Time Factors
	Treatment Outcome
	Triazoles -- administration & dosage -- adverse effects
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(17)30715-5
	info:pii/S1470-2045(17)30715-5
	info:pmid/29158011